ICON plc (ICLR) has risen sharply, recording gains of 4.85% in the past 4 weeks. However, the stock has corrected -1.24% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 4.45% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
ICON Public Limited Company is up 15.3% in the last 3-month period. Year-to-Date the stock performance stands at -2.65%. The stock has recorded a 20-day Moving Average of 0.46% and the 50-Day Moving Average is 5.39%.
ICON plc (NASDAQ:ICLR): The stock opened at $75.91 on Friday but the bulls could not build on the opening and the stock topped out at $75.91 for the day. The stock traded down to $75.19 during the day, due to lack of any buying support eventually closed down at $75.64 with a loss of -0.22% for the day. The stock had closed at $75.81 on the previous day. The total traded volume was 172,231 shares.
Also, Equity Analysts at the Jefferies maintains the rating on ICON plc (NASDAQ:ICLR). The brokerage firm has issued a Hold rating on the shares. The Analysts at the ratings agency raises the price target from $78 per share to $80 per share. The rating by the firm was issued on July 27, 2016.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.